Key Takeaways
- Normalization masks underlying strength: Revenue declined YoY only because the prior quarter benefited from a one-time sell-off of built-up inventory; this quarter reflects normalized offtake with demand described as "pretty solid."
- Product mix shift lifted gross margins: Higher sales of Rifa S relative to Rifa O improved the gross margin profile, even as EBITDA margins absorbed higher R&D and one-time costs.
- Rifapentine is the high-stakes catalyst: Management called the upside "massive" and pricing "extremely interesting," but the revenue jump depends entirely on how quickly the product is adopted following the WHO's new first-line TB guideline.
- CAPEX plan is set to more than double: The initial ~₹200 crores Phase-III plan will rise "at least double if not more," with a funding mix decision (debt vs. equity) due in six to nine months.
- What to watch next quarter: Whether the Phase-I API block commissions on the December timeline, any movement on global Rifapentine tenders, and the finalized size of the expanded CAPEX plan.
Rifapentine: The Volume & Value Thesis
- WHO tailwind: Last year, the WHO recommended Rifapentine as a first-line TB treatment over Rifampicin, cutting treatment duration from six months to four months. Management believes the four-month Rifapentine regimen actually requires a higher volume of API than the six-month Rifampicin regimen, though it noted it would double-check this assumption.
- Latent TB expansion: Beyond active TB, Rifapentine has potential in latent TB treatment, widening the addressable patient pool beyond the current Rifampicin market.
- Pricing signal: Management described current Rifapentine pricing as "extremely interesting" and confirmed margins will "definitely" be better than current product margins, otherwise moving up the value chain would not make commercial sense.
- Tender timing is the gating factor: Global tenders for Rifapentine are still expected but have not yet materialized; management expects them "during the course of a year or two years." Until tenders drop, the revenue upside remains a thesis, not a forecast.
- Volume catalyst beyond TB: Rifaximin going off-patent in certain countries in a few years, and eventually in the US, should increase volumes significantly for the company's fermentation capacity.
Dr. Sachin Patel: "It's a new kid on the block, the upside is massive, the pricing is extremely interesting right now. So, the numbers could be significantly different from what we are seeing right now, but it all depends upon how Rifapentine as a product picks up."
Capacity Build-Out & CAPEX
- Phase-I API block on track: Commissioning is targeted for December 2023, with trials and commercialization expected in the following six months. The block is multi-purpose, designed for Rifapentine and other semi-synthetic or synthetic molecules.
- Phase-I CAPEX nearly done: May require a little more to commission, but management flagged no significant overrun to the original budget.
- Phase-III plan expanding sharply: The initial ~₹200 crores plan will rise "at least double if not more" based on new projects being worked on. The number is not yet finalized and will be reported once it is.
- Funding approach: CAPEX will be spread over three years. Some will come from internal accruals, but management will "definitely" use a debt-equity mix. The decision on the exact ratio will be made over the next six to nine months.
- New fermentation capacity: Construction is underway and expected to be ready by 2025, adding to the existing base.
- Global compliance built in: New facilities are being constructed to global regulatory standards, enabling the company to target export markets beyond its current domestic customer base.
Margins: The R&D Investment Overhang
- EBITDA margin pressure had two drivers: (1) R&D expenses rose as the company hired more people and reached a stage requiring significantly higher product development investment; (2) one-off expenses were booked in the quarter.
- R&D spend is at an "action-packed high": After a long wait for the R&D block to become operational, there is now a simultaneous influx of people, materials, and activity. Management flagged that R&D expenses will have ups and downs quarter-on-quarter.
- Employee costs rose structurally: Year-on-year employee expense growth as a percentage of sales came from annual increments and new hires brought in to prepare for upcoming infrastructure.
- Utility costs are a persistent headwind: Power tariffs increased year-on-year, directly raising the cost of the company's biggest input expense. Alternatives are being planned but will take time to implement.
- Gross margin offset: The mix shift toward higher Rifa S sales helped gross margins, partially cushioning the operating expense pressure.
Dr. Sachin Patel: "So, for a long time, we were waiting for our R&D block to come up and now that it is almost there, influx of people, at the same time things happening, materials coming in. So, it's a bit of an action-packed high if I may say so."
Customer Concentration & Competitive Dynamics
- Two-customer dependency: Lupin and Optimus remain the key customers, with relationships described as "reasonably good" over the last few years. Management stated it does not intend to disturb any existing relationships while also pursuing its own aspirations.
- Pricing model shift absorbed: When asked why the customer relationship stayed intact after a pricing model change, management gave a general "win-win" characterization and declined to provide customer-side details, citing strategic confidentiality.
- Backward integration acknowledged: Management noted that "everyone has prepared themselves" to secure their business, including partners and competitors, given the significant investments required in this kind of project.
- China risk is real but rational: Management acknowledged that cross-border competition is "always a possibility" but argued that any disruptive entrant would need a good reason, "and that good reason hopefully is profitability."
- Competitor intelligence declined: Management refused to comment on whether a competitor's PLI-backed Rifa S capacity has actually started producing and supplying, or on Lupin's API sourcing strategy.
Dr. Sachin Patel: "I think everyone has prepared themselves for whatever has to be done in the future to make sure that they have their business secured, it's not just us or our partners or someone else who's in the market, everyone would take care because the investments that are required in this kind of a project are quite significant."
Operations & Working Capital
- Inventory cycle improved: Working capital benefited from a decrease in the inventory cycle. The company is currently selling whatever it produces with no carry-forward inventory, and capacity utilization is "pretty good."
- Fermentation is continuous: Manufacturing runs in 10-12 day batches. Historically, the company maintained a three-month inventory plan. Last year, inventory piled up because the plant was not stopped despite low demand, anticipating the demand that eventually arrived in Q1 of this year.
- Production philosophy: If demand is low, inventory builds up but production continues unless management sees demand declining in the foreseeable future. This creates lumpy quarter-on-quarter revenue patterns when inventory is liquidated.
- Infrastructure sharing with Themis Medicare: The two adjacent sites share some analytical services. A related party transaction approval process was put in place for amounts up to less than ₹5 lakhs, described as purely for compliance and good governance.
- Gujarat government incentives: The company is claiming incentives from the Gujarat government for the fermentation space and has applied for Gujarat Biotech Promotion Board incentives. It is not pursuing any central PLI scheme.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Phase-I API block commissioning | Trials and commercialization to follow | December 2023 |
| Quarterly revenue run-rate | Broadly around ₹40 crores | Until new API block revenue starts (mid next financial year) |
| Phase-III CAPEX finalization | At least double the initial ~₹200 crores plan | To be reported once finalized |
| Phase-III CAPEX funding decision | Debt vs. equity vs. mix | Next six to nine months |
| New fermentation capacity | Construction underway | Ready by 2025 |
| Rifapentine global tenders | Expected to materialize | During the course of a year or two years |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue | ₹39.65 cr, vs ₹47.69 cr in Q2 FY23 |
| EBITDA | ₹16.82 cr, down 31% YoY |
| EBITDA margin | 42.42%, down 875 bps YoY; impacted by R&D costs, skilled workforce investments, and one-time expenses |
| PAT | ₹12.54 cr, vs ₹18.7 cr in Q2 FY23 |
| PAT margin | 31.63% |
| EPS | ₹8.63 per share |
| H1 FY24 Revenue | ₹89.24 cr, down 3.66% YoY |
| H1 FY24 EBITDA margin | 45.19% |
| H1 FY24 PAT | ₹30.27 cr, vs ₹36 cr in H1 FY23 |
| H1 FY24 EPS | ₹20.83 per share |
| CAPEX under work-in-progress | ₹60 cr |
| Capacity utilization | More than 100%, selling as producing with no carry-forward inventory; last FY was 75–80% |
| Rifapentine API capacity built | 7 to 8 MT per month, multi-purpose facility |
| Phase-I CAPEX spent in last 2.5 years | ~₹78 cr (₹14 cr in FY22, ₹24 cr in FY23, ₹41 cr in H1 FY24) |
| New CAPEX plan indication | At least double the initial ~₹200 cr plan, not yet finalized |